Topics

FDA Approval Sought for Ibrutinib/Rituximab in Frontline CLL/SLL

11:22 EST 8 Nov 2019 | OncLive

A supplemental new drug application has been submitted to the FDA for ibrutinib (Imbruvica) for use in combination with rituximab (Rituxan) for the first-line treatment of patients ≤70 years old with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Original Article: FDA Approval Sought for Ibrutinib/Rituximab in Frontline CLL/SLL

NEXT ARTICLE

More From BioPortfolio on "FDA Approval Sought for Ibrutinib/Rituximab in Frontline CLL/SLL"

Quick Search

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...